The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

TUESDAY, May 13, 2025 (HealthDay News) — U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

Valneva is committed to upholding the highest safety standards and has engaged proactively with health authorities in all territories where IXCHIQ ® is licensed to provide timely information about all ...

The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two ...